Relationship between Glycemic Control and Cardio-Metabolic Risk Factors among Patients with Type 2 Diabetes Mellitus in Sana'a City-Yemen Relationship between Glycemic Control and Cardio-Metabolic Risk Factors among Patients with Type 2 Diabetes Mellitus in Sana'a City-Yemen (Preprint)

BACKGROUND Background: Impaired lipid metabolism in diabetic patients can lead to cardiometabolic complications.. So far, no data regarding such association are being available among Yemeni diabetic patients. OBJECTIVE Objective: This laboratory based cross-sectional study was conducted in National Center of Public Health Laboratories, ,Yemen from January 2022 to March 2022 over a period of 3 months to determine the correlation of glycemic control and lipid profile in patients with type 2 diabetes mellitus (T2 DM). METHODS A sample of 145 T2DM patients of both sexes recruited for this study. Anthropometric measures, fasting blood glucose (FBS) and fasting serum lipids (total cholesterol, TC; triglycerides, TG, low-density lipoprotein cholesterol, LDL-C and high-density lipoprotein cholesterol, HDL-C) measured. Data analyzed via descriptive statistics, Pearson’s correlation and Multiple Logistic Regression test. RESULTS The age of respondents ranged from 20 to 80 years with the mean age of 54.35±8.02 years. Among the patients male were 82 (56.6%) and female were 63 (43.4%). 105 (72.4%) were at no risk while 40 (27.6%) were at risk of having diabetic dyslipidemia. Mean body mass index (BMI), FBS and HbA1c were 25.02±5.22 kg/m2, 1.37±.489 and 1.67±0.474 respectively. Significant positive correlation of HbA1c and FBS with BMI, TC, TG, LDL-C and negative correlation with HDL-C was found. Significantly, higher TC, TG, LDL-C and HDL-C were found in poor glycemic control (HbA1c ≥ 6.0) group than good glycemic control (HbA1c < 6.0) group. CONCLUSIONS The findings of this study showed that, higher levels of glycemic parameters are significantly associated with dyslipidemia. These findings also indicate that HbA1c can be utilized for screening of high risk diabetic patients for early diagnosis of dyslipidemia and timely intervention with lipid lowering drugs. CLINICALTRIAL non